Through a pharmacological inhibition strategy of SHP2 using PHPS1 administrated in an animal mode of DN, we demonstrated that inhibiting SHP2 activity yielded therapeutic efffects on alleviating renal injury and attenuating renal inflammation in vivo, hence offering SHP2 as a new potential target in DN therapy. Here, PTPN11 is linked to liver dysplastic nodule.